Alkermes plc
ALKS
株式のランク
#2684
Alkermes plc, a biopharmaceutical company, engages in the research,... Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
株価
$42.24
時価総額
$7.09B
変化（1日）
2.47%
変化（1年）
39.59%
国
IE
取引 Alkermes plc (ALKS)
カテゴリー
Healthcare
Alkermes plc（ALKS）の利益
Jun 2026 時点の利益 TTM: $97.32M
Alkermes plc の最新の財務報告によると、同社の現在の利益は $97.32M です。2023 年には $421.52M の利益を上げ、これは 2022 年の利益 $-31.13M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Alkermes plc の利益の推移（2000 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $97.32M | -78.07% |
| 2024 | $443.75M | 5.27% |
| 2023 | $421.52M | -1,454.15% |
| 2022 | $-31.13M | -135.48% |
| 2021 | $87.73M | -190.87% |
| 2020 | $-96.54M | -51.01% |
| 2019 | $-197.06M | 55.20% |
| 2018 | $-126.97M | -11.38% |
| 2017 | $-143.27M | -33.17% |
| 2016 | $-214.39M | -4.29% |
| 2015 | $-224.01M | 1,496.73% |
| 2014 | $-14.03M | -139.58% |
| 2013 | $35.44M | 0.00% |
| 2012 | $35.44M | -130.98% |
| 2011 | $-114.39M | 146.05% |
| 2010 | $-46.49M | 4.00% |
| 2009 | $-44.70M | -134.12% |
| 2008 | $131.01M | -24.20% |
| 2007 | $172.83M | 1,539.29% |
| 2006 | $10.54M | 0.00% |
| 2005 | 0.00 | -100.00% |
| 2004 | $-75.17M | 0.00% |
| 2003 | 0.00 | -100.00% |
| 2002 | $-106.90M | 74.23% |
| 2001 | $-61.35M | 263.71% |
| 2000 | $-16.87M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | 5,320.16% |
US
|
|
| $-3.09B | -3,272.01% |
US
|
|
| $-4.02B | -4,226.79% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 1,904.37% |
NL
|
